Advertisement
Canada markets open in 1 hour 39 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7265
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    82.26
    -0.47 (-0.57%)
     

  • Bitcoin CAD

    89,484.54
    +3,309.93 (+3.84%)
     

  • CMC Crypto 200

    1,336.60
    +23.98 (+1.86%)
     

  • GOLD FUTURES

    2,392.60
    -5.40 (-0.23%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,502.00
    -45.25 (-0.26%)
     

  • VOLATILITY

    18.79
    +0.79 (+4.39%)
     

  • FTSE

    7,834.88
    -42.17 (-0.54%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6817
    -0.0004 (-0.06%)
     

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Protagonist Therapeutics, Inc. (PTGX) Investigation

ACCESSWIRE
·2 min read

NEW YORK, NY / ACCESSWIRE / September 23, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX). Investors who purchased Protagonist sharesare encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ptgx.

The investigation concerns whether Protagonist and certain of its officers and/or directors have violated federal securities laws.

On September 17, 2021, Protagonist issued a press release "announc[ing] the receipt of a verbal communication from the U.S. Food and Drug Administration (FDA) that Protagonist's clinical studies for rusfertide, an investigational product candidate currently in development, have been placed on a clinical hold." The press release stated that "[t]he clinical hold follows Protagonist's notification to the FDA of a recent non-clinical finding in a 26-week rasH2 transgenic mouse model study. The rasH2 model is designed to detect signals related to tumorigenicity, and benign and malignant subcutaneous skin tumors were observed in this study." On this news, Protagonist's stock price fell $28.60 per share, or 62%, to close at $17.53 per share on September 17, 2021.

ADVERTISEMENT

If you are aware of any facts relating to this investigation, or purchased Protagonist shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/ptgx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/665261/Bronstein-Gewirtz-Grossman-LLC-Notifies-Investors-of-Protagonist-Therapeutics-Inc-PTGX-Investigation